Abliva is a brand dedicated to developing medicines for the treatment of primary mitochondrial diseases. With a focus on delivering mitochondrial health, Abliva aims to improve the lives of individuals affected by these diseases. Their portfolio includes a range of projects with mechanisms of action suitable for different types of primary mitochondrial diseases.

Primary mitochondrial disease affects the ability of cells to convert energy, and its manifestations vary depending on the affected organs and the number of dysfunctional mitochondria. Thanks to advancements in our understanding of the mutations underlying mitochondrial diseases, Abliva is better equipped to identify and treat patients. Abliva's in-house research and development capabilities have played a vital role in the creation of their portfolio.

They collaborate with partners, advisors, and experts in the field to ensure the development and delivery of effective treatments. As a brand, Abliva is committed to transparency and provides comprehensive financial reports, including annual and interim reports, to its investors. They prioritize corporate governance and adhere to strict guidelines.

To stay updated on Abliva's progress and receive relevant updates, interested individuals can subscribe to their newsletter or explore their website for more information